The resulting double mutants BB7865 risA aroA and BB7865 risA dapE were characterized as promising vaccine candidates, which are able to confer protection against colonization of the lower respiratory tract after sub-lethal challenge with the wild type strain.
Introduction
Bordetella bronchiseptica infects a broad range of mammalian hosts, causing acute or chronic respiratory infections, often resulting in oligosymptomatic or asymptomatic clinical forms (Goodnow, 1980) . B. bronchiseptica constitutes both, a primary etiological agent and a predisposing factor for secondary infections, thereby exacerbating disease symptoms provoked by other pathogens (e.g. bacteria and viruses), thus resulting in a broad range of diseases, such as pneumonia and atrophic rhinitis in swine, infectious tracheobronchitis in dogs (kennel cough), and bronchopneumonia in other domestic animals like cats (Mattoo and Cherry, 2005) . B. bronchiseptica efficiently colonizes the ciliated respiratory epithelium and persists in the lower respiratory tract for several weeks, thereby establishing chronic infections (Mattoo and Cherry, 2005) . The persistence of B. bronchiseptica is facilitated by the expression of virulence determinants tightly controlled by a two-component regulatory system encoded in the bvgAS locus.
Until now, most B. bronchiseptica strains are sensitive to aminoglycosides such as amikacin and gentamycin, as well as to extended-spectrum third-generation penicillins, and tetracyclines (Woolfrey and Moody, 1991; Mattoo and Cherry, 2005) . However, antimicrobial therapy seems to be of limited value in animals (Bemis et al., 1977; Speakman et al., 2000; Zhao et al., 2011) . In addition, antibiotic treatment of food animals could also have dramatic consequences for human health (Aarestrup et al., 2008) . Therefore, prophylaxis of diseases caused by B. bronchiseptica through vaccination rather than by treatment of infected animals seems to be the only 3 reasonable choice. Current vaccines against B. bronchiseptica are given by the systemic route stimulating protective antibody responses against severe forms of disease (Gopinathan et al., 2007) . However, these vaccines do not prevent B. bronchiseptica infections. Thus, despite vaccination animals continue to be carriers, which in turn predispose them to other infectious agents (Sukumar et al., 2009) . Furthermore, recent studies indicated that immunity elicited after parenteral vaccination is less protective than infection-induced immunity. Hence, the induction of mucosal immunity seems to be crucial in order to prevent subsequent infections . To stimulate protective immune responses it might be also essential to maintain the expression of the virulence factors necessary during the infection process. A strategy which enables attenuation without compromising the antigenicity of a vaccine strain is based on the disruption of metabolic pathways, such as inactivation of the genes encoding for the 5-enolpyruvyl-shikimate-3-phosphate synthase (aroA) and the N-succinyl-DAP desuccinylase (dapE), which are crucial for bacterial in vivo growth and survival (Gilvarg, 1960; Dugal et al., 1992; Jungnitz et al., 1998; McArthur et al., 2003) .
B. bronchiseptica not only invades both nonphagocytic and phagocytic cells (Guzman et al., 1994a; Forde et al., 1998) , but also efficiently persists within these cells (Guzman et al., 1994b; Schipper et al., 1994; Banemann and Gross, 1997; Zimna et al., 2001 ). This in turn facilitates bacterial escape from host clearance mechanisms and might subsequently promote chronic infection (Schipper et al., 1994; Harvill et al., 1999) . The underlying mechanisms allowing B. bronchiseptica to survive intracellularly seem to be bvg-independent, as bvg mutants survived to a similar or even greater extent than their wild type counterparts (Guzman et al., 1994b; Schipper et al., 1994; Banemann and 4 Gross, 1997) . Mutants in the two-component regulatory system RisAS, which is required for bacterial resistance to oxidative stress, exhibited impaired intracellular survival and in vivo persistence (Jungnitz et al., 1998) . In vaccine development, the impairment of the capacity to survive intracellularly of a given mutant is an important correlate for an attenuated phenotype, but it might also lead to a reduced in vivo survival (i.e. decreased antigen load), which might result in impaired immune responses. Thus, our strategy was to target critical metabolic pathways of B. bronchiseptica in combination with a mutation in the ris locus. The double mutants showed an adequate safety profile and conferred protective immunity, representing promising attenuated vaccines against this pathogen, as well as scaffold for multicomponent live veterinary vaccines.
Results

Double attenuated mutants of B. bronchiseptica showed impaired intracellular survival
Single and double B. bronchiseptica mutants were generated as described in Experimental procedures. The ability of single and double mutants in the selected target genes to invade and persist within eukaryotic cells was evaluated using the human epithelial cell line (HeLa), as well as the murine macrophage-and DC-like cell lines J774A.1 and CB1, respectively (Fig. 1) . The single metabolic mutant BB7865 aroA exhibited a considerable impaired capacity to persist within HeLa cells (23% of the wild 5 type after 24 h). In contrast, dysfunction of the N-succinyl-DAP succinylase (dapE) seems to affect the intracellular survival of BB7865 dapE to a lesser extent (50%). As expected, this capacity has been further impaired in the double mutants (BB7865 risA aroA, 17% and BB7865 risA dapE, 39%; Fig. 1) . A similar survival pattern has been obtained evaluating the survival capacity within the murine derived professional antigen presenting DC-like CB1 cells (Fig. 1) . Again, the strains harboring the dapE mutation seem to be slightly more efficient in intracellular survival, as compared to the strains harboring the aroA mutation (18% and 17% vs 14% and 14%, respectively). However, in contrast to what has been observed in HeLa cells, this capability was not further impaired in the double mutants (Fig. 1) . Interestingly, the BB7865 aroA mutant exhibit a considerably improved in vitro survival within J774A.1 cells, even after 24 h of infection (146% of the wild type strain, respectively; Fig. 1 ). This higher recovery could be related to lower levels of toxicity, associated with lower expression of the autotransporter protein pertactin (PRN) by this mutant, as B. bronchiseptica has been reported to mediate the cytotoxicity to macrophages via bvg-regulated factors, including PRN (Forde et al., 1999) . Furthermore, the BB7865 dapE mutant was also able to persist within J774A.1 cells more efficiently, as compared to the other cell types (80% of the parental strain). In contrast, only a few CFU of the BB7865 risA strain were present 24 h after infection (10%), which is in accordance with previous observations (Jungnitz et al., 1998) .
However, similar to what was observed for HeLa cells, the introduction of a second mutation further reduced the capacity of intracellular survival of strains BB7865 risA aroA and BB7865 risA dapE (45% and 11% of the values obtained for BB7865).
Interestingly, while the dapE mutants seemed to be more efficient in surviving within 6 both HeLa and CB1 cells, as compared to the aroA mutants, the latter persists more efficiently within J774A.1 cells (Fig. 1) .
Taken together, destruction of metabolic pathways by mutation resulted in an impaired capacity of the mutant strains to survive within eukaryotic cells. In addition, introduction of a second mutation (risA) further reduced this ability.
Vaccination of mice with live attenuated derivatives of B. bronchiseptica by i.n.
route induces strong humoral and cellular immune responses
Previous studies demonstrated the importance of both humoral and cellular immunity in prevention of B. bronchiseptica infections (Pishko et al., 2004; Kirimanjeswara et al., 2005; Pilione and Harvill, 2006) . Clearance of this pathogen from the respiratory tract is mainly triggered by opsonizing antibodies (IgG2a subclass), Th1 immune responses characterized by high IFN-production, and TLR4-mediated recruitment and activation of immune cells, followed by neutrophil-mediated CR3-and FcR-dependent phagocytic killing mechanisms (Pishko et al., 2004; Kirimanjeswara et al., 2005; Pilione and Harvill, 2006) . Thus, we evaluated the immune responses triggered following vaccination with the attenuated derivatives of B. bronchiseptica.
Consistent with previous studies (Gueirard et al., 1996) , IgG production was detected in all of the groups between 11-18 days following priming (Fig. 2) . Although after the challenge the highest titers were observed in mice immunized with the single mutants BB7865 aroA, BB7865 dapE and BB7865 risA, similar titers were stimulated by the double mutants BB7865 risA aroA and BB7865 risA dapE. Interestingly, while similar or even increased levels of IgG1 compared to the values of IgG2a were stimulated following immunization with the mutant strains, IgG2a was the predominant subclass present 10 days after challenge of vaccinated mice with the wild type strain BB7865 (Fig. 3) . These findings affirm the results of Gopinathan et al. showing that vaccination and infection with B. bronchiseptica induced different type of antibody responses (Gopinathan et al., 2007) . However, only low levels of B. bronchiseptica-specific secretory IgA (sIgA) could be observed in mucosal secretions of vaccinated animals (Fig. 4) . Furthermore, no significant levels of antigen-specific sIgA were detected in lung homogenates of immunized mice, as compared to the control group. Conversely, the highest sIgA titers were observed in bronchoalveolar lavage fluids (BALF) of immunized mice, whereupon BB7865 aroA stimulated the strongest sIgA response, followed by BB7865 risA dapE, BB7865 risA and BB7865 dapE , whereas no sIgA have been detected in BALF of mice immunized with BB7865 risA aroA (Fig. 4) . On the other hand, immunization with the double mutants seemed to stimulate higher sIgA titers in nasal washes (NW), as compared to those of mice vaccinated with the single mutants (Fig. 4) .
Besides humoral immune responses, an efficient stimulation of cellular immunity seems to be critical to confer optimal protection against B. bronchiseptica. In this context, the clearance of this pathogen is known to be facilitated by a Th1-dominated cellular response, but there is increasing evidence that B. bronchiseptica is able to redirect the polarization of the adaptive immune response from a dominant Th1 towards a Th17 response pattern (Siciliano et al., 2006) . Interestingly, BB7865 aroA was the only strain stimulating the same cytokine profile as the wild type strain, showing high values of IL-17 producing cells followed by IFN- producing cells (Fig. 5) . In contrast, all other mutant strains stimulated a Th1-dominated cytokine pattern, as indicated by the high numbers Only modest and no significant differences were detected between experimental groups following vaccination (Fig. 5 ).
Vaccination of mice using the novel attenuated B. bronchiseptica strains inhibits colonization of the lower and upper respiratory tract after challenge with wild type
B. bronchiseptica
To investigate the capacity of the generated mutants to trigger protective immune responses following vaccination by intranasal (i.n.) route, bacterial loads in NW and lung homogenates of immunized mice challenged with the wild type strain BB7865 were investigated. We also assessed the capacity of the mutants to persist following immunization. To distinguish between BB7865, BB7865 risA and their attenuated derivatives bacterial suspensions were plated on appropriate selective media and the number of CFU were determined. Remarkably, while the single mutants BB7865 aroA and BB7865 dapE were able to persist over the whole course of the experiment ( clearance of the wild type strain from the lungs of infected mice ( Fig. 6F, H ). On the other hand, vaccination of mice with BB7865 risA aroA seems to be slightly more efficient at protecting mice against colonization of the upper respiratory tract by the wild type strain (factor 40 compared to unvaccinated control group) with respect to immunization with BB7865 risA dapE (factor 7 compared to unvaccinated control group) (Fig. 6B, D) .
Immunization of mice using the novel attenuated B. bronchiseptica strains reduces neutrophil influx in the lungs following challenge with wild type bacteria
To evaluate the safety profile of the new attenuated mutants, BALF of vaccinated animals were collected at different time intervals to perform a kinetic analysis of the local influx of different cellular subpopulations (Fig. 7) . In all experimental groups except the control group (non-vaccinated), an early self-limited influx of lymphocytes and neutrophils was observed on day 3 after immunization ( Fig. 7A ). This initial recruitment of neutrophils to the lungs during the course of B. bronchiseptica infections seems to be triggered by TLR4 (Mann et al., 2004) . While the influx of neutrophils completely subsided already after 7 days in animals vaccinated with the BB7865 aroA mutant, it persisted in animals receiving BB7865 dapE, BB7865 risA, BB7865 risA aroA and BB7865 risA dapE for 7 to 13 days, and in the case of BB7865 dapE between 14 and 21 days (Fig. 7B, C) . In addition, BALF of vaccinated mice also showed an influx of monocytic cells, whereas the counts for eosinophils were negligible at all-time points.
Interestingly, on day 21 (Fig. 7D ) a second cellular influx was observed in all groups, which was accompanied by an increment in the number of epithelial cells. This could be explained by a progressive damage of the epithelial integrity as a result of a secondary release of bacterial products and/or desquamation of infected cells, which in turn could act as chemo-attractants for lymphocytes and neutrophils. However, only marginal levels of epithelial cells have been observed in BALF of mice immunized with BB7865 aroA, suggesting only moderate tissue damage (Fig. 7D) . Following challenge of vaccinated animals with the wild type B. bronchiseptica strain, a strong influx of neutrophils was observed. Interestingly, the influx seemed to be less massive in BALF of mice immunized with the double mutants (Fig. 7E) . Furthermore, vaccinated animals showed a significant reduction in the number of neutrophils compared to naïve mice already on day 3 post challenge and values returned to baseline levels already on day 10 post challenge ( Fig. 7E-G) . In contrast, the strongest influx of neutrophils and lymphocytes was observed in BALF of control animals (PBS + challenge) returning to baseline levels on day 21 after the challenge (Fig. 7H) . Subsequent to the challenge, a strong increment was also evident in the counts for monocytes/macrophages with the highest values reached on day 3 post challenge ( Fig. 7F) . Thus, the effect of immunization with attenuated mutants was impressive in all groups, leading to consistent reduction in neutrophils influx.
Discussion
B. bronchiseptica has a broad host range and contributes to a number of acute respiratory syndromes in food-producing confinement-reared animals, as well as in pets (Goodnow, 1980; Rajeev et al., 2003) . B. bronchiseptica also plays a significant role as predisposing factor for secondary infections caused by bacteria or viruses (Sukumar et al., 2009) . Although different vaccines are already available, respiratory infections caused by B. bronchiseptica are still widespread, since existent vaccines are not completely satisfactory in terms of efficacy and/or safety (King, 2004) . Thus, there is still a critical need for more efficient vaccines.
It was previously reported that infected animals are resistant to re-infection by B.
bronchiseptica, suggesting that infection-induced immunity is more effective than responses stimulated by whole cell or subunit vaccines . Thus, a successful strategy must be directed toward mimicking natural infections. This approach would allow triggering protection against both disease (i.e. symptoms) and infection (i.e. colonization). Therefore, we developed attenuated metabolic mutants of B. bronchiseptica based on the inactivation of the genes aroA and dapE, which encode for enzymes involved in the pre-chorismate and the DAP/lysine pathways, respectively. Studies performed in other bacterial species suggested that inactivation of these genes could result in mutants with an appropriate safety profile (Hess et al., 1996; Gunel-Ozcan et al., 1997; Sizemore et al., 1997) .
Thus, metabolic mutants were generated by insertion mutagenesis based on homologous recombination. To improve the safety profile of the strains, the metabolic mutations were combined with a second mutation in the locus encoding the twocomponent regulatory system RisAS, which is critical for bacterial intracellular survival (Jungnitz et al., 1998) . As a result, the risk of reversion to virulence by recombination has been further minimized.
To assess the level of attenuation of the mutants, infection assays were performed. In agreement with previous studies, the BB7865 aroA and BB7865 risA mutants exhibit impaired survival within HeLa cells (Jungnitz et al., 1998; Stenson et al., 2005) . In contrast, the capacity of the single mutant BB7865 dapE was much less affected. As expected, when investigating the double mutants, their capacity to persist intracellularly was reduced even more. Similar survival patterns have been observed infecting CB1 cells. However, the survival rates were even more impaired as compared to those observed in HeLa cells. In contrast to what observed for HeLa and CB1 cells, BB7865 aroA and BB7865 dapE were able to persist within J774A.1 cells to the same extent or even more efficient than their parenteral strain. Only when the risA mutation was additionally introduced this capacity was drastically impaired. The higher recovery rates observed for the mutants could be explained by a diminished cytotoxic effect, whereby 13 reduced cellular damage prevents bacterial killing due to antibiotic influx from the culture medium. In fact, the mutants exhibit a weaker expression of PRN (data not shown), which mediates cytotoxicity on macrophages (Forde et al., 1999) . The type III secretion system is another potential factor, since mutants were recovered from J774A.1 cells in significantly higher numbers than the wild type strain (Fennelly et al., 2008) . Next, we investigated the level of attenuation of the B. bronchiseptica mutants in vivo as well as their potential to stimulate efficient immune responses. Mice infected intranasally with either mutant did not show any signs of toxicity (e.g. weight loss or reduced motility), suggesting an adequate safety profile of the mutants. While all double mutants were cleared from the respiratory tract within 14 to 21 days, the single mutants persisted for at least 46 days in both the lower and upper respiratory tract. This is in contrast to what previously reported for an aroA mutant which was cleared from lungs after one week (Stevenson and Roberts, 2004) . However, since the number of bacteria in our experimental conditions were very low, this discrepancy might be negligible.
Nevertheless, the observed results are consistent with the impaired capacity of the double mutants to survive intracellularly and clearly demonstrate an efficient attenuation of B. bronchiseptica by introducing double or even single mutations.
Despite the efficient attenuation of the mutants, immunization of mice by intranasal route stimulated strong humoral and cellular immune responses. A considerable increment in
Bordetella-specific IgG titers was observed, which is of importance since IgG constitutes a main effector for achieving efficient bacterial clearance. Former studies reported that rises in IgG and IgA titers in dogs vaccinated with an attenuated B. bronchiseptica strain correlated with protection (Bey et al., 1981; Stevenson and Roberts, 2002) . IgG levels detected in sera of mice vaccinated with either the single or the double mutants differed only marginally. The mutants containing the aroA or dapE mutation stimulated similar levels of IgG production in sera, as well as IgA production in local mucosal surfaces.
However, BB7865 risA dapE protected mice more efficiently against colonization of the lower respiratory tract, but less efficiently against colonization of the upper respiratory tract, as compared to its single mutant counterparts. In contrast, when mice were immunized with the aroA based mutants, exactly the opposite was observed. By and large, the immunity stimulated by the mutants was more efficient in the lower than in the upper respiratory tract. This correlates with higher B. bronchiseptica-specific IgA titers detected in BALF than in NW of vaccinated animals, and it is consistent with former reports showing that the sIgA titer correlates with the level of protection (Bey et al., 1981; Wolfe et al., 2007) .
Protective immunity against B. bronchiseptica is also supported by efficient cellular responses (Roberts et al., 1993; McArthur et al., 2003) . All Bordetella mutants stimulated proliferative responses following intranasal immunization (data not shown). In line with previous reports (Pathak et al., 2010) , immunization with our metabolic mutants by intranasal route stimulated only small numbers of IL-4 secreting cells. In contrast, the number of IFN- producing cells was significantly increased. Thus, a clear Th1 dominated response pattern with limited stimulation of Th2 cells was promoted, which in turn is known to facilitate B. bronchiseptica clearance (Pathak et al., 2010) . As reported before, immune responses stimulated by Bordetella vaccines differ from those observed following infection (Gopinathan et al., 2007) . Interestingly, we observed the same analyzing the ratios of IgG1 and IgG2a subclasses stimulated by aroA and dapE mutants following vaccination, which just shifted in favor of IgG2a after mice were challenged with the wild type strain. However, immunization with the mutant strains also promoted a significant increment of IL-17 producing cells, which is consistent with recent findings showing that Bordetella redirects adaptive immune responses from a Th1 dominated towards a Th17 response pattern (Siciliano et al., 2006) . This might in turn support persistence of Bordetella within the respiratory tract. However, the exact role of Th17 helper cells in B. bronchiseptica infections is not yet fully understood, since it was suggested that stimulation of a mixed Th1/Th17 response by B. pertussis correlates with protection (Fedele et al., 2011) .
Protective immunity against B. bronchiseptica relies on adaptive immunity. Thus, it is not surprising that clearance of wild type Bordetella from the lower respiratory tract of mice vaccinated with either the dapE or aroA mutants correlates with the immune responses stimulated by them. However, protection against B. bronchiseptica also requires an efficient activation of the innate immune system, especially of neutrophils and macrophages, which seems to be TLR4 dependent Pathak et al., 2010) . Therefore, we evaluated the influx of neutrophils and monocytes following vaccination with our mutant strains and challenge with wild type Bordetella. In all immunized mice an early influx of neutrophils and lymphocytes has been observed. This influx is short lived, returning to basal cellular levels already after 2 weeks, when the influx of monocytes reaches its maximum (Pathak et al., 2010) . Interestingly, directly after challenge a massive re-influx of neutrophils followed by monocytes occurred.
However, basal levels were reached much faster in vaccinated mice, between 3 (neutrophils) and 10 days (macrophages) post challenge, thereby reducing the risk of 16 tissue damage. Further evaluation of tissue damage using histological analysis of lungs showed almost no pathological changes in the lungs of mice immunized with BB7865 risA aroA and BB7865 risA dapE on days 14-21 after the challenge with wild type BB7865 strain (data not shown).
Taken together, we identified BB7865 risA aroA and BB7865 risA dapE as attenuated derivatives of B. bronchiseptica, which are able to promote efficient protective immunity against a sub-lethal challenge with virulent bacteria. Thus, they represent promising candidate vaccine strains for further development. However, their safety and efficacy in vaccine target animal species still remains to be established. Furthermore, to allow their implementation in the veterinary field, the generation of defined deletion mutants will be essential. Ideally, the deletion mutants should be combined with a marker mutation, which would allow differentiation between infected and vaccinated animals. It is expected that the resulting strains could be also exploited as a delivery system for heterologous antigens from other respiratory pathogens, such as Pasteurella multocida. .
Experimental procedures
Generation of attenuated derivatives of B. bronchiseptica B. bronchiseptica strain BB7865, a human nasopharyngal isolate (Gross and Rappuoli, 1989; Stibitz et al., 1989; Schipper et al., 1994) , and its derivative BB7865 risA, which harbors a mini-transposon insertion in the ris locus (Jungnitz et al., 1998) , were selected to generate attenuated vaccine strains carrying mutations in genes encoding for the 5-enolpyruvyl-shikimate-3-phosphate synthase (aroA), and for the N-succinyl-DAP desuccinylase (dapE).
Inactivation of the Bordetella genes aroA and dapE was performed using the suicide vector pFUS2 (Antoine et al., 2000) . and PstI/BamHI (dapE) fragments were cloned into pFUS2. In order to transfer the resulting pFUS2 derivatives into the B. bronchiseptica strains BB7865 and BB7865 risA biparental matings were performed using the mobilizing strain E. coli SM10pir as donor strain (Simon et al., 1983) . Bacterial conjugation was performed on 0.45 µm sterile filters placed onto Bordet-Gengou agar plates (Difco Detroit, MI, USA) with donor:recipient ratios of 10:1, 4:1 and 1:1. Plates were incubated at 37°C for 4 h or overnight.
Homologous recombination events resulted in the integration of the pFUS2 derivatives into the corresponding chromosomal gene, thereby generating the single and double insertion mutants BB7865 aroA, BB7865 dapE, BB7865 risA aroA and BB7865 risA dapE, respectively. Transconjugants were selected according to the antibiotic resistance patterns of the recipient strains BB7865 and BB7865 risA (streptomycin and kanamycin), as well as gentamycin as marker for pFUS2 derivative integration.
Infection assay
The eukaryotic 
Sample collection
Blood samples were collected via the retro-orbital plexus by using 40 μl glass capillaries after animals were anesthetized with Isoflurane. To collect the BALF, the trachea was intubated and the lung was flushed with 1 ml of sterile ice-cold PBS. In order to obtain NW, the nasal cavity was flushed with 200 μl of sterile ice-cold PBS and the flow through was collected in sterile 1.5 ml tubes. BALF and NW were immediately placed on ice or stored at -20°C until further processing. Lungs were aseptically removed and placed in 4 ml of sterile ice-cold PBS. Then, lungs were homogenized using a Polytron PT 1200 
Statistical analysis
Statistical analysis was performed using the software Sigma Stat version 3.1 for Windows or GraphPad Prism software (GraphPad Software, Inc., La Jolla, USA). For comparison between two groups the Student's t, Mann Whitney, and Two-Way ANOVA Multiple Comparison tests were used. Differences were considered significant at *P <0.05, **P <0.01, and ***P <0.001. 
